| D008297 |
Male |
|
Males |
|
| D008444 |
Maxillary Sinus Neoplasms |
Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms. |
Cancer of Maxillary Sinus,Maxillary Sinus Cancer,Neoplasms, Maxillary Sinus,Cancer, Maxillary Sinus,Cancers, Maxillary Sinus,Maxillary Sinus Cancers,Maxillary Sinus Neoplasm,Neoplasm, Maxillary Sinus |
|
| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D009325 |
Nausea |
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. |
|
|
| D012074 |
Remission Induction |
Therapeutic act or process that initiates a response to a complete or partial remission level. |
Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions |
|
| D002294 |
Carcinoma, Squamous Cell |
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) |
Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas |
|
| D004305 |
Dose-Response Relationship, Drug |
The relationship between the dose of an administered drug and the response of the organism to the drug. |
Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response |
|
| D004341 |
Drug Evaluation |
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. |
Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation |
|
| D005260 |
Female |
|
Females |
|
| D005641 |
Tegafur |
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. |
1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207 |
|